The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.
 
Christopher Manz
No Relationships to Disclose
 
Eva Ruiz-Hispán
No Relationships to Disclose
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Bernard Doger de Spéville Uribe
No Relationships to Disclose
 
Daniel Morillo
No Relationships to Disclose
 
Ignacio Mahillo
No Relationships to Disclose
 
Jesus Garcia-Foncillas
No Relationships to Disclose
 
William J. Ferrell
No Relationships to Disclose
 
Ian J Barnett
No Relationships to Disclose
 
Emily R Schriver
No Relationships to Disclose
 
Ravi Bharat Parikh
Stock and Other Ownership Interests - GNS Healthcare; Google; Merck; Onc.AI; Thyme Care
Honoraria - Wake Forest School of Medicine
Consulting or Advisory Role - Archetype Therapeutics; Biofourmis; ConcertAI; Credit Suisse; G1 Therapeutics; Humana; Merck; NanOlogy; Thyme Care
Research Funding - Emerson Collective; Humana; Mendel AI; Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - Technology to integrate patient-reported outcomes into electronic health record algorithms
Travel, Accommodations, Expenses - The Oncology Institute of Hope and Innovation
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS